Biogen (NSDQ:BIIB) has scrapped its development plans for gosuranemab (BIIB092) after the drug candidate failed to hit the primary endpoint in a Phase 2 trial.
Biogen’s aducanumab made waves recently, becoming the first Alzheimer’s drug to win FDA approval in recent memory. Not all, however, are happy with that fact.
Aducanumab is an amyloid beta-protein inhibitor while gosuranemab was an anti-tau antibody.
In the TANGO Study, gosuranemab did not appear to have a treatment benefit in several measures in the 78-week study. Such measures included the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog 13), the Alzheimer Disease Cooperative Study Activity of Daily Living (ADCS-ADL), the Mini-Mental State Examination (MMSE) and the Functional Assessment Questionnaire (FAQ).
Biogen will present the findings from the gosuranemab study at an upcoming medical congress.
The biotech iPierian first developed the antibody, which was initially known as IPN007. Bristol-Myers Squibb acquired rights to the antibody in 2014 when BMS acquired iPierian. Biogen licensed PN007, which it dubbed BIIB092, in 2017.
BIIB092 had also failed to demonstrate efficacy in the 2019 PASSPORT trial, which had a duration of one year.
Filed Under: clinical trials, Drug Discovery, Neurological Disease
